Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst DowngradesByBenzinga•08 Sept 2023Benzinga - by Vandana Singh, Benzinga Editor. BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14, down from...
US To Spend Up To $300 Mln Over Six Years On Alzheimer's Data Platform - ReutersByInvesting.com•03 Apr 2023